NFKB1 and Miyoshi myopathy: Constitutive NF-κB pathway activation accounts for MM cell unresponsiveness to several classical drugs, such as melphalan and dexamethasone [65,66,67] and to novel pharmacologic agents under current investigation, such as aurora kinase inhibitors [68].